Operational Issues in Clinical Trial Disclosure of Global Trials

被引:0
|
作者
Shown M. Pelletier
Maureen A. Strange
Barbara J. Godlew
机构
[1] Business Operations,Clinical Trial Transparency, Global Development Medical Affairs
[2] Bristol-Myers Squibb,Medical Quality, Clinical Trial Registry, Global Medical Quality
[3] Eli Lilly and Company,undefined
[4] The FAIRE Company,undefined
[5] LLC,undefined
关键词
Maine; Clinical trial disclosure; FDAAA; Operations; Process;
D O I
暂无
中图分类号
学科分类号
摘要
In hospitals and clinics around the world, ordinary people place their health and their very lives in the hands of researchers who test new experimental drugs for safety and effectiveness. The public and legislators worldwide have expressed increasing interest in understanding how clinical trials are conducted and the results of those trials. The list of stakeholders has grown substantially in recent years to include medical and scientific academia, government agencies, regulatory authorities, and advocacy groups. Quite logically, stakeholders’ interests have shifted slightly from the registration of clinical trial protocol information to the posting of clinical trial results upon trial completion. Protocol registration and results reporting requirements are staggering, diverse, and complex. This article provides a look at industry experience with the operational challenges of clinical trial registries and results databases that the pharmaceutical, medical device, and biotechnology industry, and academia face when providing clinical trial information.
引用
收藏
页码:253 / 264
页数:11
相关论文
共 50 条
  • [1] Operational Issues in Clinical Trial Disclosure of Global Trials
    Pelletier, Shawn M.
    Strange, Maureen A.
    Godlew, Barbara J.
    DRUG INFORMATION JOURNAL, 2010, 44 (03): : 253 - 264
  • [2] Oncology Clinical Trials in Africa: Emerging and Operational Issues
    Odedina, Folakemi T.
    Ginsburg, Ophira
    JCO GLOBAL ONCOLOGY, 2020, 6 : 929 - 931
  • [3] Disclosure of Possible Trial Termination to Participants of Interventional Clinical Trials
    Hutchinson, Nora
    Gelinas, Luke
    Zarin, Deborah
    Bierer, Barbara E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (13): : 1116 - 1117
  • [4] Global Franchising Operational Issues
    Asarpota, Jaishree
    4TH INTERNATIONAL CONFERENCE ON MARKETING AND RETAILING 2013 (INCOMAR 2013), 2014, 130 : 193 - 203
  • [5] Disclosure of clinical trials in children
    Bonati, M
    Pandolifini, C
    Clavenna, A
    SCIENCE, 2004, 305 (5689) : 1401 - 1401
  • [6] Clinical Trial Disclosure: Global Overview and Implications of New Laws and Guidelines
    Thomas, Kathy B.
    Joergensen, Merete
    Lynch, Gerard
    Rubison, Michael
    Porter, Brandon D.
    Sayers, Jacqueline
    Tesch, Claudia
    DRUG INFORMATION JOURNAL, 2010, 44 (03): : 213 - 225
  • [7] Clinical Trial Disclosure: Global Overview and Implications of New Laws and Guidelines
    Kathy B. Thomas
    Merete Joergensen
    Gerard Lynch
    Michael Rubison
    Brandon D. Porter
    Jacqueline Sayers
    Claudia Tesch
    Drug information journal : DIJ / Drug Information Association, 2010, 44 : 213 - 225
  • [8] Global clinical trials: Quality assurance methodology for site based, global clinical trial ratings
    Spear, C.
    Busner, J.
    Vieta, E.
    Bartko, J.
    Bealer, R.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 311 - 311
  • [9] Precautionary Harm Disclosure in Clinical Trials
    Wu, Kevin Chien-Chang
    AMERICAN JOURNAL OF BIOETHICS, 2009, 9 (08): : 43 - 45